Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
si-circTFDP2
- Development stage
- Preclinical
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
si-circTFDP2 is a small interfering RNA (siRNA) designed to specifically target and silence the circular RNA circTFDP2. Research indicates that circTFDP2 is an exosome-derived circular RNA that promotes the progression of prostate cancer by protecting Poly(ADP-ribose) polymerase 1 (PARP1) from cleavage by caspase-3, thereby maintaining DNA repair capacity and cell survival in malignant cells. By knocking down circTFDP2, si-circTFDP2 facilitates PARP1 cleavage, increases DNA damage, and inhibits the growth and progression of prostate cancer cells. It is primarily used in preclinical research to investigate the role of circular RNAs in oncogenesis and as a potential therapeutic strategy for prostate cancer.
- Other names
- siRNA targeting circTFDP2circTFDP2 siRNAcircTFDP-2 siRNAcircTFDP 2 siRNA
02
Targets
circTFDP2 (circular RNA TFDP2)
Beyond the preview
Go deeper on si-circTFDP2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on si-circTFDP2.